Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 1

Conditions

Severe Acute Respiratory Syndrome 1Mastocytosis 1Hypersensitivity 1Hematopoietic and Lymphatic System Neoplasm 1COVID-19 1

Interventions

pembrolizumab 521Specimen Handling 383Carboplatin 376Magnetic Resonance Spectroscopy 334Cisplatin 331Nivolumab 309Cyclophosphamide 298Radiotherapy 257Paclitaxel 254Biopsy 235Gemcitabine 234Bevacizumab 218Dexamethasone 169durvalumab 167Oxaliplatin 163Capecitabine 159Rituximab 156Fluorouracil 149venetoclax 147Docetaxel 147atezolizumab 143Drug Therapy 143Etoposide 141Doxorubicin 134Ipilimumab 129Prednisone 121Radiosurgery 120Lenalidomide 118Leucovorin 113fludarabine 109

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × BNT162 Vaccine × 1 year × Clear all
NCT07390968 2026-02-09

Self-Amplifying mRNA COVID-19 Vaccine (LUNAR-COV19) Versus Comirnaty Vaccine in Adult Hematopoietic Cell Transplant Patients

Fred Hutchinson Cancer Center

Phase 2 Not yet recruiting
56 enrolled

Hematopoietic and Lymphatic System Neoplasm

NCT04761822 2025-08-12

SARS

National Institute of Allergy and Infectious Diseases (NIAID)

Phase 2 Completed
746 enrolled 28 charts
Myeloid

COVID-19, Hypersensitivity, Mastocytosis, Severe Acute Respiratory Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡